Skip to content
DataLookout
Menu

NCT07920783

A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

The incidence of adverse events (AEs)
Timeframe: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12
The incidence of serious adverse events (SAEs)
Timeframe: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12

Secondary (16)

Changes in STAT6
Changes in TARC
Cmax
AUC0-t
AUC0-inf
Show 11 moreShow less
Tmax
λz
t1/2
CL/F
Vz/F
Changes in IgE
Cmax,ss
Cmin,ss
Cav,ss
AUC0-τ,ss
Tmax,ss

Arms and interventions

GLR2053 TabletsExperimental

Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of GLR2053.

PlaceboPlacebo comparator

Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.

Drugs: GLR2053 Tablets, Placebo

Sites

1 site in 1 country

  • Beijing GoBroad HospitalBeijing, China